Australia Molecular Diagnostics Market Size & Outlook
Australia Molecular Diagnostics Market, 2018-2030 (US$M)
Global Market
Related Markets
Australia molecular diagnostics market highlights
- The Australia molecular diagnostics market generated a revenue of USD 254.3 million in 2024 and is expected to reach USD 356.6 million by 2030.
- The Australia market is expected to grow at a CAGR of 5.6% from 2025 to 2030.
- In terms of segment, reagents was the largest revenue generating product in 2024.
- Reagents is the most lucrative product segment registering the fastest growth during the forecast period.
Molecular diagnostics market data book summary
| Market revenue in 2024 | USD 254.3 million |
| Market revenue in 2030 | USD 356.6 million |
| Growth rate | 5.6% (CAGR from 2025 to 2030) |
| Largest segment | Reagents |
| Fastest growing segment | Reagents |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Instruments, Reagents |
Other key industry trends
- In terms of revenue, Australia accounted for 1.0% of the global molecular diagnostics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China molecular diagnostics market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,497.8 million by 2030.
This rising cancer burden underscores the growing demand for advanced diagnostic solutions, particularly in molecular diagnostics. As early detection and personalized treatment become increasingly critical in improving cancer outcomes, the need for precise, rapid diagnostic tools will drive innovation and growth in the molecular diagnostics market, enabling better diagnosis, monitoring, and treatment of cancer on a global scale.
Australia has two established national screening programs—the National Bowel Cancer Screening Program and the National Cervical Screening Program—that utilize self-test kits for the early detection of cancer. These self-tests allow individuals to participate in these programs, which have proven clinical effectiveness similar to point-of-care testing.
The success of these programs highlights the growing role of molecular diagnostics in cancer detection, driving demand for more accessible and effective diagnostic solutions in the market, particularly in the context of early detection and prevention.
No credit card required*
Publish Date: Jan 08, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Molecular Diagnostics Market Scope
Molecular Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Abbott Laboratories | View profile | 114,000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | www.abbottinvestor.com |
| Becton Dickinson & Co | View profile | 73,000 | 1 Becton Drive, Franklin Lakes, NJ, United States, 07417-1880 | www.bd.com |
| BioMerieux SA | View profile | 13,982 | Marcy l’Etoile, Lyon, France, 69280 | www.biomerieux.com |
| Siemens Healthineers AG ADR | View profile | 71,400 | Siemensstr. 3, Forchheim, BY, Germany, 91301 | www.siemens-healthineers.com |
| Danaher Corp | View profile | 63,000 | 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701 | www.danaher.com |
| Illumina Inc | View profile | 9,300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | www.illumina.com |
| Agilent Technologies Inc | View profile | 17,700 | 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 | www.agilent.com |
| Bio-Rad Laboratories Inc | View profile | 8,030 | 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 | www.bio-rad.com |
| Qiagen NV | View profile | 5,900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | www.qiagen.com |
| Hologic Inc | View profile | 6,990 | 250 Campus Drive, Marlborough, MA, United States, 01752 | www.hologic.com |
Australia Molecular Diagnostics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Molecular Diagnostics Market Outlook will help companies and investors design strategic landscapes.
Reagents was the largest segment with a revenue share of 65.47% in 2024.
Horizon Databook has segmented the Australia molecular diagnostics market based on instruments, reagents covering the revenue growth of each sub-segment from 2018 to 2030.
This rising cancer burden underscores the growing demand for advanced diagnostic solutions, particularly in molecular diagnostics. As early detection and personalized treatment become increasingly critical in improving cancer outcomes, the need for precise, rapid diagnostic tools will drive innovation and growth in the molecular diagnostics market, enabling better diagnosis, monitoring, and treatment of cancer on a global scale.
Australia has two established national screening programs—the National Bowel Cancer Screening Program and the National Cervical Screening Program—that utilize self-test kits for the early detection of cancer. These self-tests allow individuals to participate in these programs, which have proven clinical effectiveness similar to point-of-care testing.
The success of these programs highlights the growing role of molecular diagnostics in cancer detection, driving demand for more accessible and effective diagnostic solutions in the market, particularly in the context of early detection and prevention.
- Australia Molecular Diagnostics Market Product Outlook (Revenue, USD Million , 2018-2030)
- Instruments
- Reagents
- Others Product
- Australia Molecular Diagnostics Market Test Location Outlook (Revenue, USD Million , 2018-2030)
- Point of care
- Self test or OTC
- Central laboratories
- Australia Molecular Diagnostics Market Technology Outlook (Revenue, USD Million , 2018-2030)
- PCR
- ISH
- INAAT
- Chips and microarrays
- Mass spectrometry
- Sequencing
- TMA
- Others Technology
- Australia Molecular Diagnostics Market Application Outlook (Revenue, USD Million , 2018-2030)
- Oncology
- Pharmacogenomics
- Infectious disease
- Genetic testing
- Neurological disease
- Cardiovascular disease
- Microbiology
- Others Application
Reasons to subscribe to Molecular Diagnostics Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Molecular Diagnostics Market Outlook databook
- Our clientele includes a mix of Molecular Diagnostics Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia Molecular Diagnostics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Australia Molecular Diagnostics Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Australia Molecular Diagnostics Market, 2018-2030 (US$M)
Australia Product - Molecular Diagnostics Market Statistics, 2024 - 2030 (US$M)
